Scholarlink

Background <p>Combination pharmacotherapy with tamsulosin plus tadalafil could be a superior strategy compared to conventional monotherapy with tamsulosin in patients with Benign prostatic obstruction (BPO) with or without erectile dysfunction.</p> Methodology <p>A comprehensive search was conducted across PubMed, the Cochrane Library, and Embase to identify studies assessing the efficacy and safety of combination therapy compared with monotherapy in patients with BPO with or without erectile dysfunction. A random effects meta-analysis was performed with R version 4.4.1 using the 'meta' package.</p> Results <p>We included eleven RCTs, with a combined total of 940 patients. Our analysis demonstrated that the combination therapy is associated with a greater reduction in overall IPSS (MD = − 2.78, 95% CI − 3.97 to − 1.59; P &lt; 0.01), IIEF (MD = 2.98, 95% CI 1.64 to 4.33; P &lt; 0.01), QoL score (MD = − 0.58, 95% CI − 0.86 to − 0.30; P &lt; 0.01), PVR (MD = − 9.34, 95% CI = -15.52 to − 3.16; P &lt; 0.01) and a significant improvement in Qmax (MD = 1.04, 95% CI 0.43 to 1.64; P &lt; 0.01) as compared to tamsulosin alone. However, combination therapy resulted in a higher incidence of pain (OR = 5.66, 95% CI 2.56 to 12.52; P &lt; 0.01) and other adverse events (OR = 2.97, 95% CI 1.60 to 5.49; P &lt; 0.01).</p> Conclusion <p>Combination therapy with tamsulosin and tadalafil demonstrated superior efficacy over tamsulosin monotherapy in reducing LUTS, improving quality of life, and enhancing erectile function. However, it was associated with a higher incidence of adverse effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tamsulosin plus Tadalafil compared with Tamsulosin alone for benign prostate hyperplasia in patients with or without erectile dysfunction: a meta-analysis and meta-regression of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月11日

查看全文
  • Tallal Mushtaq Hashmi,
  • Rohma Zia,
  • Hadiah Ashraf,
  • Momina Siddiqui,
  • Ali Haider,
  • Valencia Rumampouw,
  • Momina Aslam Khan,
  • Mushood Ahmed,
  • Javed Iqbal

摘要

Background

Combination pharmacotherapy with tamsulosin plus tadalafil could be a superior strategy compared to conventional monotherapy with tamsulosin in patients with Benign prostatic obstruction (BPO) with or without erectile dysfunction.

Methodology

A comprehensive search was conducted across PubMed, the Cochrane Library, and Embase to identify studies assessing the efficacy and safety of combination therapy compared with monotherapy in patients with BPO with or without erectile dysfunction. A random effects meta-analysis was performed with R version 4.4.1 using the 'meta' package.

Results

We included eleven RCTs, with a combined total of 940 patients. Our analysis demonstrated that the combination therapy is associated with a greater reduction in overall IPSS (MD = − 2.78, 95% CI − 3.97 to − 1.59; P < 0.01), IIEF (MD = 2.98, 95% CI 1.64 to 4.33; P < 0.01), QoL score (MD = − 0.58, 95% CI − 0.86 to − 0.30; P < 0.01), PVR (MD = − 9.34, 95% CI = -15.52 to − 3.16; P < 0.01) and a significant improvement in Qmax (MD = 1.04, 95% CI 0.43 to 1.64; P < 0.01) as compared to tamsulosin alone. However, combination therapy resulted in a higher incidence of pain (OR = 5.66, 95% CI 2.56 to 12.52; P < 0.01) and other adverse events (OR = 2.97, 95% CI 1.60 to 5.49; P < 0.01).

Conclusion

Combination therapy with tamsulosin and tadalafil demonstrated superior efficacy over tamsulosin monotherapy in reducing LUTS, improving quality of life, and enhancing erectile function. However, it was associated with a higher incidence of adverse effects.